Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -80.97% is 19% above its 5-year average of -100.49%, near the high end of its 5-year range (-257.60%–-24.76%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.46% above its 12-month average of -143.22%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -80.97%.
RETURN ON EQUITY (ROE)
-80.97%
RETURN ON EQUITY (ROE) AVG TTM
-143.22%
RETURN ON EQUITY (ROE) AVG 3Y
-138.04%
RETURN ON EQUITY (ROE) AVG 5Y
-100.49%
RETURN ON EQUITY (ROE) AVG 10Y
-37.48%
RETURN ON EQUITY (ROE) AVG 15Y
-32.18%
RETURN ON EQUITY (ROE) AVG 20Y
-17.47%
CURRENT VS TTM AVG
+43.46%
CURRENT VS 3Y AVG
+41.34%
CURRENT VS 5Y AVG
+19.42%
CURRENT VS 10Y AVG
-116.04%
CURRENT VS 15Y AVG
-151.64%
CURRENT VS 20Y AVG
-363.38%
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-124.89%
vs the sector median at left
Apyx Medical Corporation
Market Cap
$109.49M
Return on Equity (ROE)
-80.97%
TTM Avg
-143.22%
3Y Avg
-138.04%
5Y Avg
-100.49%
Market Cap
$109.93M
Return on Equity (ROE)
-87.45%
TTM Avg
455.42%
3Y Avg
120.34%
5Y Avg
63.42%
Market Cap
$108.39M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$111.17M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
Market Cap
$106.23M
Return on Equity (ROE)
-60.82%
TTM Avg
-19.88%
3Y Avg
-19.08%
5Y Avg
-15.27%
Market Cap
$113.77M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$114.24M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
Market Cap
$104.07M
Return on Equity (ROE)
-116.28%
TTM Avg
-71.19%
3Y Avg
-41.66%
5Y Avg
-29.50%
Market Cap
$116.59M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $109.49M | -80.97% | -143.22% | -138.04% | -100.49% |
| Immunic, Inc. (IMUX)vs › | $109.93M | -87.45% | 455.42% | 120.34% | 63.42% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | -99.67% | -40.73% | 98.81% | 13.93% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | -44.29% | -31.86% | -53.29% | -49.85% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | -60.82% | -19.88% | -19.08% | -15.27% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -43.47% | 9.13% | -18.50% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | -93.44% | -8.16% | 13.24% | 13.24% |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | -116.28% | -71.19% | -41.66% | -29.50% |
| Genelux Corporation (GNLX)vs › | $116.59M | -209.73% | -196.07% | -130.72% | -67.26% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | 129.36% | -24207.46% | -16163.58% |
ROE
-81.0%
ROA
-14.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -80.97% |
| 2026-03-31 | -71.45% |
| 2025-12-31 | -77.10% |
| 2025-09-30 | -248.63% |
| 2025-06-30 | -237.96% |
| 2025-03-31 | -190.63% |
| 2024-12-31 | -165.12% |
| 2024-09-30 | -257.60% |
| 2024-06-30 | -192.36% |
| 2024-03-31 | -112.61% |
| 2023-12-31 | -70.08% |
| 2023-09-30 | -45.45% |
| 2023-06-30 | -44.51% |
| 2023-03-31 | -57.48% |
| 2022-12-31 | -61.69% |
| 2022-09-30 | -45.58% |
| 2022-06-30 | -38.33% |
| 2022-03-31 | -32.72% |
| 2021-12-31 | -28.25% |
| 2021-09-30 | -27.04% |
| 2021-06-30 | -24.76% |
| 2021-03-31 | -24.73% |
| 2020-12-31 | -18.67% |
| 2020-09-30 | -25.20% |
| 2020-06-30 | -25.07% |
| 2020-03-31 | -23.29% |
| 2019-12-31 | -26.85% |
| 2019-09-30 | -22.53% |
| 2019-06-30 | 69.74% |
| 2019-03-31 | 71.73% |
| 2018-12-31 | 72.93% |
| 2018-09-30 | 73.54% |
| 2018-06-30 | -15.18% |
| 2018-03-31 | -20.08% |
| 2017-12-31 | -22.98% |
| 2017-09-30 | -21.14% |
| 2017-06-30 | -19.01% |
| 2017-03-31 | -14.95% |
| 2016-12-31 | -15.06% |
| 2016-09-30 | -23.45% |
| 2016-06-30 | -25.63% |
| 2016-03-31 | -29.76% |
| 2015-12-31 | -22.94% |
| 2015-09-30 | -37.17% |
| 2015-06-30 | -39.44% |
| 2015-03-31 | -32.64% |
| 2014-12-31 | -368.13% |
| 2014-09-30 | -149.09% |
| 2014-06-30 | -98.95% |
| 2014-03-31 | -114.66% |
| 2013-12-31 | -20.34% |
| 2013-09-30 | -7.39% |
| 2013-06-30 | -5.76% |
| 2013-03-31 | 0.10% |
| 2012-12-31 | 2.70% |
| 2012-09-30 | -2.41% |
| 2012-06-30 | -2.10% |
| 2012-03-31 | -0.88% |
| 2011-12-31 | 0.49% |
| 2011-09-30 | -1.70% |
| 2011-06-30 | -1.97% |
| 2011-03-31 | -3.67% |
| 2010-12-31 | -7.05% |
| 2010-09-30 | -0.60% |
| 2010-06-30 | -0.78% |
| 2010-03-31 | -0.14% |
| 2009-12-31 | 2.83% |
| 2009-09-30 | 3.14% |
| 2009-06-30 | 5.20% |
| 2009-03-31 | 11.62% |
| 2008-12-31 | 10.78% |
| 2008-09-30 | 12.11% |
| 2008-06-30 | 12.74% |
| 2008-03-31 | 11.84% |
| 2007-12-31 | 14.30% |
| 2007-09-30 | 15.46% |
| 2007-06-30 | 18.37% |
| 2007-03-31 | 17.40% |
| 2006-12-31 | 19.08% |
| 2006-09-30 | 19.97% |
| 2006-06-30 | 16.04% |
| 2006-03-31 | 9.46% |
| 2005-12-31 | 4.12% |
| 2005-09-30 | 5.13% |
| 2005-06-30 | 9.03% |
| 2005-03-31 | 14.53% |
| 2004-12-31 | 16.33% |
| 2004-09-30 | 10.15% |
| 2004-06-30 | 9.64% |
| 2004-03-31 | 11.06% |
| 2003-12-31 | 9.13% |
| 2003-09-30 | 8.01% |
| 2003-06-30 | 1.63% |
